Review





Similar Products

96
MedChemExpress abt 737
Abt 737, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abts/ABT-737/pmc13626084-309-0-8
Average 96 stars, based on 1 article reviews
abt 737 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
TargetMol cas 115144 35 9 abt 737
Cas 115144 35 9 Abt 737, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abts/ABT-737/pm42392927-277-93-97
Average 94 stars, based on 1 article reviews
cas 115144 35 9 abt 737 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

97
MedChemExpress abt 263
A, Western blot analysis of Myc-CaP cells following 6-day treatment with DMSO, docetaxel (3.75μM), palbociclib (1μM), or PF-06873600 (500nM). B-C, Heatmaps displaying BCL2 ( B ) and IAP ( C ) family gene expression in Myc-CaP cells treated with DMSO, Nutlin-3 (10μM), palbociclib (1μM), T/P (25nM/1μM), PF-06873600 (500nM), alisertib (500nM), etoposide (500nM), or docetaxel (3.75μM) for 6 days from RNA-seq analysis (n=3/group). D, Representative clonogenic images of Myc-CaP cells pre-treated with DMSO or indicated drugs as in B , followed by replatement and treatment with <t>ABT-263</t> (1μM) or DMSO for 48 hrs. Quantification of Crystal Violet staining is shown (n=3/group). E, Representative clonogenic images of Myc-CaP cells pre-treated with docetaxel for 6 days, followed by replatement and treatment with LCL161 (1μM), TNFα (160ng/ml), and/or Z-VAD (20μM) for 48 hrs. Quantification of Crystal Violet staining is shown (n=3/group). F, Western blot analysis of Myc-CaP cells pre-treated with docetaxel for 6 days, followed by replatement and treatment with DMSO, ABT-263, or LCL161/TNFα for 6 hrs. G, Quantification of clonogenic growth in Myc-CaP cells pre-treated with 3.75μM docetaxel for 6 days, followed by replatement and treatment with ABT-263 (1μM), LCL161 (1μM), TNFα (160ng/ml), MCC950 (1μM), and/or Nec-1 (10μM) for 48 hrs (n=3/group). H, Cytokine array analysis in Myc-CaP cells treated as in F . Data represent mean ± SEM. Statistical significance was determined by one-way ANOVA. NS, not significant.
Abt 263, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abts/Navitoclax/pmc13679333-137-0-3
Average 97 stars, based on 1 article reviews
abt 263 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

94
MedChemExpress 1 abt
(A) Feeding of CYP P450 inhibitors 1-Aminobenzotriazole <t>(1-ABT)</t> or piperonylbutoxide (PBO) does not restore the inhibition of erebosis by heme. 1-ABT with Ho RNAi and PBO with Mrp5 RNAi result in >50% class0 and no class2, which is similar to Ho RNAi or Mrp5 RNAi with DMSO. (B) ROS levels are not increased by Mrp5 RNAi . Using hsFLP system, Mrp5 RNAi was induced only in GFP+ cells. ROS probe dihydroethidium (DHE, magenta) is not changed in GFP+ Mrp5 RNAi cells (dashed line). (C) Ho RNAi or Mrp5 RNAi does not increase signals of lipid peroxide probe Liperfluo (green), while bleomycin increases them. (D) Feeding of a reducing agent N-acetylcysteine (NAC) does not increase erebosis. P values were calculated using Fisher’s exact test (A, D) and adjusted with the Benjamini–Hochberg method (D). Scale bars, 50 μm.
1 Abt, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abts/1-Aminobenzotriazole/pmc13489435-228-9-10
Average 94 stars, based on 1 article reviews
1 abt - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

97
MedChemExpress abt 199
(A) Feeding of CYP P450 inhibitors 1-Aminobenzotriazole <t>(1-ABT)</t> or piperonylbutoxide (PBO) does not restore the inhibition of erebosis by heme. 1-ABT with Ho RNAi and PBO with Mrp5 RNAi result in >50% class0 and no class2, which is similar to Ho RNAi or Mrp5 RNAi with DMSO. (B) ROS levels are not increased by Mrp5 RNAi . Using hsFLP system, Mrp5 RNAi was induced only in GFP+ cells. ROS probe dihydroethidium (DHE, magenta) is not changed in GFP+ Mrp5 RNAi cells (dashed line). (C) Ho RNAi or Mrp5 RNAi does not increase signals of lipid peroxide probe Liperfluo (green), while bleomycin increases them. (D) Feeding of a reducing agent N-acetylcysteine (NAC) does not increase erebosis. P values were calculated using Fisher’s exact test (A, D) and adjusted with the Benjamini–Hochberg method (D). Scale bars, 50 μm.
Abt 199, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abts/Venetoclax/10__1038_slash_s41420___026___03298___2-59-11-9
Average 97 stars, based on 1 article reviews
abt 199 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

97
MedChemExpress abt
(A) Feeding of CYP P450 inhibitors 1-Aminobenzotriazole <t>(1-ABT)</t> or piperonylbutoxide (PBO) does not restore the inhibition of erebosis by heme. 1-ABT with Ho RNAi and PBO with Mrp5 RNAi result in >50% class0 and no class2, which is similar to Ho RNAi or Mrp5 RNAi with DMSO. (B) ROS levels are not increased by Mrp5 RNAi . Using hsFLP system, Mrp5 RNAi was induced only in GFP+ cells. ROS probe dihydroethidium (DHE, magenta) is not changed in GFP+ Mrp5 RNAi cells (dashed line). (C) Ho RNAi or Mrp5 RNAi does not increase signals of lipid peroxide probe Liperfluo (green), while bleomycin increases them. (D) Feeding of a reducing agent N-acetylcysteine (NAC) does not increase erebosis. P values were calculated using Fisher’s exact test (A, D) and adjusted with the Benjamini–Hochberg method (D). Scale bars, 50 μm.
Abt, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abts/Navitoclax/bio_rxiv__64898__2026__08__03__740778-70-9-17
Average 97 stars, based on 1 article reviews
abt - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

97
MedChemExpress veliparib abt 888 medchem express
(A) Feeding of CYP P450 inhibitors 1-Aminobenzotriazole <t>(1-ABT)</t> or piperonylbutoxide (PBO) does not restore the inhibition of erebosis by heme. 1-ABT with Ho RNAi and PBO with Mrp5 RNAi result in >50% class0 and no class2, which is similar to Ho RNAi or Mrp5 RNAi with DMSO. (B) ROS levels are not increased by Mrp5 RNAi . Using hsFLP system, Mrp5 RNAi was induced only in GFP+ cells. ROS probe dihydroethidium (DHE, magenta) is not changed in GFP+ Mrp5 RNAi cells (dashed line). (C) Ho RNAi or Mrp5 RNAi does not increase signals of lipid peroxide probe Liperfluo (green), while bleomycin increases them. (D) Feeding of a reducing agent N-acetylcysteine (NAC) does not increase erebosis. P values were calculated using Fisher’s exact test (A, D) and adjusted with the Benjamini–Hochberg method (D). Scale bars, 50 μm.
Veliparib Abt 888 Medchem Express, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abts/Olaparib/pm41935526-166-269-271
Average 97 stars, based on 1 article reviews
veliparib abt 888 medchem express - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

Image Search Results


A, Western blot analysis of Myc-CaP cells following 6-day treatment with DMSO, docetaxel (3.75μM), palbociclib (1μM), or PF-06873600 (500nM). B-C, Heatmaps displaying BCL2 ( B ) and IAP ( C ) family gene expression in Myc-CaP cells treated with DMSO, Nutlin-3 (10μM), palbociclib (1μM), T/P (25nM/1μM), PF-06873600 (500nM), alisertib (500nM), etoposide (500nM), or docetaxel (3.75μM) for 6 days from RNA-seq analysis (n=3/group). D, Representative clonogenic images of Myc-CaP cells pre-treated with DMSO or indicated drugs as in B , followed by replatement and treatment with ABT-263 (1μM) or DMSO for 48 hrs. Quantification of Crystal Violet staining is shown (n=3/group). E, Representative clonogenic images of Myc-CaP cells pre-treated with docetaxel for 6 days, followed by replatement and treatment with LCL161 (1μM), TNFα (160ng/ml), and/or Z-VAD (20μM) for 48 hrs. Quantification of Crystal Violet staining is shown (n=3/group). F, Western blot analysis of Myc-CaP cells pre-treated with docetaxel for 6 days, followed by replatement and treatment with DMSO, ABT-263, or LCL161/TNFα for 6 hrs. G, Quantification of clonogenic growth in Myc-CaP cells pre-treated with 3.75μM docetaxel for 6 days, followed by replatement and treatment with ABT-263 (1μM), LCL161 (1μM), TNFα (160ng/ml), MCC950 (1μM), and/or Nec-1 (10μM) for 48 hrs (n=3/group). H, Cytokine array analysis in Myc-CaP cells treated as in F . Data represent mean ± SEM. Statistical significance was determined by one-way ANOVA. NS, not significant.

Journal: Cancer research

Article Title: Senolytic Interventions Enhance the Anti-metastatic Activity of Chemotherapy in Prostate Cancer

doi: 10.1158/0008-5472.CAN-26-0493

Figure Lengend Snippet: A, Western blot analysis of Myc-CaP cells following 6-day treatment with DMSO, docetaxel (3.75μM), palbociclib (1μM), or PF-06873600 (500nM). B-C, Heatmaps displaying BCL2 ( B ) and IAP ( C ) family gene expression in Myc-CaP cells treated with DMSO, Nutlin-3 (10μM), palbociclib (1μM), T/P (25nM/1μM), PF-06873600 (500nM), alisertib (500nM), etoposide (500nM), or docetaxel (3.75μM) for 6 days from RNA-seq analysis (n=3/group). D, Representative clonogenic images of Myc-CaP cells pre-treated with DMSO or indicated drugs as in B , followed by replatement and treatment with ABT-263 (1μM) or DMSO for 48 hrs. Quantification of Crystal Violet staining is shown (n=3/group). E, Representative clonogenic images of Myc-CaP cells pre-treated with docetaxel for 6 days, followed by replatement and treatment with LCL161 (1μM), TNFα (160ng/ml), and/or Z-VAD (20μM) for 48 hrs. Quantification of Crystal Violet staining is shown (n=3/group). F, Western blot analysis of Myc-CaP cells pre-treated with docetaxel for 6 days, followed by replatement and treatment with DMSO, ABT-263, or LCL161/TNFα for 6 hrs. G, Quantification of clonogenic growth in Myc-CaP cells pre-treated with 3.75μM docetaxel for 6 days, followed by replatement and treatment with ABT-263 (1μM), LCL161 (1μM), TNFα (160ng/ml), MCC950 (1μM), and/or Nec-1 (10μM) for 48 hrs (n=3/group). H, Cytokine array analysis in Myc-CaP cells treated as in F . Data represent mean ± SEM. Statistical significance was determined by one-way ANOVA. NS, not significant.

Article Snippet: ABT-263 (Navitoclax; HY-10087, MedChemExpress) was dissolved in DMSO to yield 100 mM stock solutions and then diluted in corn oil (Sigma) to a final concentration of 5 mM prior to injecting into animals.

Techniques: Western Blot, Analysis, Gene Expression, RNA Sequencing, Staining

A, Schematic of Myc-CaP orthotopic transplantation into FVB mice and treatment schedule. Created in BioRender. Zhou, L. (2026) https://BioRender.com/bz5q63y . B , Representative IHC staining of Myc-CaP prostate tumors from mice treated with vehicle, docetaxel (10mg/kg), ABT-263 (50mg/kg), and/or LCL161 (75mg/kg) for 2 weeks. Scale bar, 100μm. Quantification of number of p21 + /p16 + senescent cells and CC3 + /CC8 + dead cells/field is shown inset (n=3 mice/group). Images and values for vehicle/docetaxel conditions are the same shown in Fig. 4B . C , Cytokine array analysis of Myc-CaP tumors from mice treated as in B (n=2 mice/group). Statistical significance could not be determined due to low sample number. Values for vehicle/docetaxel conditions are the same shown in Fig. 4C ; Supplementary Fig.6A . D-F , Flow cytometry analysis of CD8 + T cell numbers and activation markers ( D ), iMCs ( E ), and DC populations ( F ) in Myc-CaP tumors from mice treated as in B (n=7-8 mice/group). Values for vehicle/docetaxel conditions are the same shown in Fig. 4E ; Supplementary Fig.6C . G , Waterfall plot of the response of Myc-CaP tumors to treatment as in B (n=5-8 mice/group). Values for vehicle/docetaxel conditions are the same shown in Fig. 4G . Each bar represents an individual mouse. H, Quantification of ascites volume in Myc-CaP tumor-bearing mice treated as in B (n=7-8 mice/group). Values for vehicle/docetaxel conditions are the same shown in Fig.4H . I, Representative H&E staining of liver metastases (outlined in black) in Myc-CaP tumor-bearing mice treated as in B. Scale bar, 50μm. Quantification of percentage of mice with liver metastasis is shown (n=3-5 mice/group). Images and values for vehicle/docetaxel conditions are the same shown in Fig. 4I . Data represent mean ± SEM. Statistical significance was determined by one-way ANOVA. NS, not significant.

Journal: Cancer research

Article Title: Senolytic Interventions Enhance the Anti-metastatic Activity of Chemotherapy in Prostate Cancer

doi: 10.1158/0008-5472.CAN-26-0493

Figure Lengend Snippet: A, Schematic of Myc-CaP orthotopic transplantation into FVB mice and treatment schedule. Created in BioRender. Zhou, L. (2026) https://BioRender.com/bz5q63y . B , Representative IHC staining of Myc-CaP prostate tumors from mice treated with vehicle, docetaxel (10mg/kg), ABT-263 (50mg/kg), and/or LCL161 (75mg/kg) for 2 weeks. Scale bar, 100μm. Quantification of number of p21 + /p16 + senescent cells and CC3 + /CC8 + dead cells/field is shown inset (n=3 mice/group). Images and values for vehicle/docetaxel conditions are the same shown in Fig. 4B . C , Cytokine array analysis of Myc-CaP tumors from mice treated as in B (n=2 mice/group). Statistical significance could not be determined due to low sample number. Values for vehicle/docetaxel conditions are the same shown in Fig. 4C ; Supplementary Fig.6A . D-F , Flow cytometry analysis of CD8 + T cell numbers and activation markers ( D ), iMCs ( E ), and DC populations ( F ) in Myc-CaP tumors from mice treated as in B (n=7-8 mice/group). Values for vehicle/docetaxel conditions are the same shown in Fig. 4E ; Supplementary Fig.6C . G , Waterfall plot of the response of Myc-CaP tumors to treatment as in B (n=5-8 mice/group). Values for vehicle/docetaxel conditions are the same shown in Fig. 4G . Each bar represents an individual mouse. H, Quantification of ascites volume in Myc-CaP tumor-bearing mice treated as in B (n=7-8 mice/group). Values for vehicle/docetaxel conditions are the same shown in Fig.4H . I, Representative H&E staining of liver metastases (outlined in black) in Myc-CaP tumor-bearing mice treated as in B. Scale bar, 50μm. Quantification of percentage of mice with liver metastasis is shown (n=3-5 mice/group). Images and values for vehicle/docetaxel conditions are the same shown in Fig. 4I . Data represent mean ± SEM. Statistical significance was determined by one-way ANOVA. NS, not significant.

Article Snippet: ABT-263 (Navitoclax; HY-10087, MedChemExpress) was dissolved in DMSO to yield 100 mM stock solutions and then diluted in corn oil (Sigma) to a final concentration of 5 mM prior to injecting into animals.

Techniques: Transplantation Assay, Immunohistochemistry, Analysis, Flow Cytometry, Activation Assay, Staining

(A) Feeding of CYP P450 inhibitors 1-Aminobenzotriazole (1-ABT) or piperonylbutoxide (PBO) does not restore the inhibition of erebosis by heme. 1-ABT with Ho RNAi and PBO with Mrp5 RNAi result in >50% class0 and no class2, which is similar to Ho RNAi or Mrp5 RNAi with DMSO. (B) ROS levels are not increased by Mrp5 RNAi . Using hsFLP system, Mrp5 RNAi was induced only in GFP+ cells. ROS probe dihydroethidium (DHE, magenta) is not changed in GFP+ Mrp5 RNAi cells (dashed line). (C) Ho RNAi or Mrp5 RNAi does not increase signals of lipid peroxide probe Liperfluo (green), while bleomycin increases them. (D) Feeding of a reducing agent N-acetylcysteine (NAC) does not increase erebosis. P values were calculated using Fisher’s exact test (A, D) and adjusted with the Benjamini–Hochberg method (D). Scale bars, 50 μm.

Journal: PLOS Biology

Article Title: Heme acts as a metabolic brake on erebosis in the Drosophila gut

doi: 10.1371/journal.pbio.3003942

Figure Lengend Snippet: (A) Feeding of CYP P450 inhibitors 1-Aminobenzotriazole (1-ABT) or piperonylbutoxide (PBO) does not restore the inhibition of erebosis by heme. 1-ABT with Ho RNAi and PBO with Mrp5 RNAi result in >50% class0 and no class2, which is similar to Ho RNAi or Mrp5 RNAi with DMSO. (B) ROS levels are not increased by Mrp5 RNAi . Using hsFLP system, Mrp5 RNAi was induced only in GFP+ cells. ROS probe dihydroethidium (DHE, magenta) is not changed in GFP+ Mrp5 RNAi cells (dashed line). (C) Ho RNAi or Mrp5 RNAi does not increase signals of lipid peroxide probe Liperfluo (green), while bleomycin increases them. (D) Feeding of a reducing agent N-acetylcysteine (NAC) does not increase erebosis. P values were calculated using Fisher’s exact test (A, D) and adjusted with the Benjamini–Hochberg method (D). Scale bars, 50 μm.

Article Snippet: Flies were fed with standard food with 15 μM 1-ABT (MedChemExpress HY-103389) or PBO (MedChemExpress HY-B1198) at 30 °C for 7 days.

Techniques: Inhibition